Prevalence and distribution of hepatitis C virus genotypes in Spain during the 2000-2015 period (the GEHEP 005 study).

We report the largest study on the prevalence and distribution of HCV genotypes in Spain (2000-2015), and we relate them with clinical, epidemiological and virological factors. Patients from 29 hospitals in 10 autonomous communities (Andalusia, Aragon, Castilla-Leon, Catalonia, Galicia, Canary Islands, Madrid Community, Valencian Community, Murcia Region and Basque Country) have been studied. Annual distribution of HCV genotypes and subtypes, as well as gender, age, transmission route, HIV and/or HBV coinfection, and treatment details were recorded. We included 48595 chronically HCV-infected patients with the following characteristics: median age 51 years (IQR, 44-58), 67.9% male, 19.1% HIV-coinfected, 23.5% HBV-coinfected. Parenteral transmission route was the most frequent (58.7%). Genotype distribution was 66.9% GT1 (24.9% subtype 1a and 37.9% subtype 1b), 2.8% GT2, 17.3% GT3, 11.4% GT4 and 0.1% GT5 and 0.02% GT6. LiPA was the most widely HCV genotyping test used (52.4%). HCV subtype 1a and genotypes 3 and 4 were closely associated with male gender, parenteral route of infection and HIV and HBV coinfection; in contrast, subtype 1b and genotype 2 were associated with female gender, nonparenteral route and mono-infection. Age was related to genotype distribution, and different patterns of distribution and biodiversity index were observed between different geographical areas. Finally, we describe how treatment and changes in transmission routes may have affected HCV genotype prevalence and distribution patterns. We present the most recent data on molecular epidemiology of hepatitis C virus in Spain. This study confirms that genotype distributions vary with age, sex, HIV and HBV coinfection and within geographical areas and epidemiological groups.

Incorporation of age into patient early warning scores significantly improves mortality prediction.

BACKGROUND: Age is a critical factor for the assessment of patients attended by emergency medical services (EMSs). However, how age modifies early warning scores' (EWSs) predictive ability should be unveiled. AIM: To determine how age influences the performance of EWS [National Early Warning Score 2 (NEWS2), VitalPAC-Early Warning Score (ViEWS), Rapid Acute Physiology Score (RAPS) and modified Rapid Emergency Medicine Score (mREMS)] to predict 2-day mortality. The secondary objective was to determine the performance of EWSs at different age ranges. DESIGN: A prospective, observational study performed between November 2019 and July 2023. METHODS: A multicenter, ambulance-based study, considering 38 basic life support units and six advanced life support units referring to four tertiary care hospitals. Eligible patients were adults recruited from among all phone requests for emergency assistance who were later evacuated to emergency departments. The primary outcome was 2-day in-hospital mortality (includes all-cause mortality). The main measures were demographical and vital signs needed for EWS calculation. RESULTS AND DISCUSSION: A total of 8028 participants fulfilled the inclusion criteria, with 7654 survivors and 374 non-survivors. Among age ranges, the 2-day mortality was 2.8% for the ≤44 years, 3.3% for the 45-64 years, 4.1% for the 65-74 years and 6.7% for the ≥75-year age group. The inclusion of age significantly improved the Area Under the Curve (AUC) in all the scores (P = 0.006 for non-age-adjusted mREMS, P = 0.001 for NEWS2, P = 0.002 for ViEWS, P = 0.028 for RAPS, all compared with their counterparts with age). CONCLUSION: Our results demonstrated that the incorporation of age into the EWS improved the performance of the scores. These results will allow the EMS to improve patient management and resource optimization by including an easy-to-obtain variable.

Association between prehospital lactate categories with short- and long-term mortality: a prospective, observational multicenter study.

BACKGROUND: Lactate is an already recognized biomarker for short-term mortality in emergency medical services (EMS). However, how different levels of lactate are associated with short-, mid- and long-term outcomes should be unveiled. AIM: To determine how different categories of hyperlactatemia are associated with mortality. We also aim to clinically characterize hyperlactatemia groups. DESIGN: A multicenter, prospective, observational study performed between January 2019 and February 2022, considering 48 basic life support units and 5 advanced life support units referring to 4 tertiary care hospitals (Spain). Patients were recruited from phone requests for emergency assistance in adults, evacuated to emergency departments. The primary outcome was in-hospital mortality from any cause within the first to the 365-day period following EMS attendance. The main measures were demographical and biochemical variables, prehospital advanced life support techniques used and patient condition categorized in 24 diseases. METHODS: Univariate and Cox regression analysis. RESULTS: A total of 5072 participants fulfilled inclusion criteria. Group #1 (non-hyperlactatemia) was composed of 2389 subjects (47.1%), Group #2 (mild hyperlactatemia) of 1834 (36.1%), Group #3 (hyperlactatemia) of 333 (6.6%) and, finally, Group #4 (severe hyperlactatemia) of 516 (10.2%). The 1-day mortality was 0.2%, 1.1%, 9% and 22.3% in the four lactate groups, respectively. Long-term mortality (365 days) was 10.2%, 22.7%, 38.7% and 46.7% in the four lactate groups, respectively. Differences between patients' conditions of lactatemia groups were also found. CONCLUSIONS: Our results demonstrated that prehospital lactate categories were associated with short- and long-term outcomes in a different manner. These results will allow EMS to establish different risk states according to the prehospital lactate categories.

Surveillance of Vermont wildlife in 2021-2022 reveals no detected SARS-CoV-2 viral RNA.

Previous studies have documented natural infections of SARS-CoV-2 in various domestic and wild animals. More recently, studies have been published noting the susceptibility of members of the Cervidae family, and infections in both wild and captive cervid populations. In this study, we investigated the presence of SARS-CoV-2 in mammalian wildlife within the state of Vermont. 739 nasal or throat samples were collected from wildlife throughout the state during the 2021 and 2022 harvest season. Data was collected from red and gray foxes (Vulpes vulples and Urocyon cineroargentus, respectively), fishers (Martes pennati), river otters (Lutra canadensis), coyotes (Canis lantrans), bobcats (Lynx rufus rufus), black bears (Ursus americanus), and white-tailed deer (Odocoileus virginianus). Samples were tested for the presence of SARS-CoV-2 via quantitative RT-qPCR using the CDC N1/N2 primer set and/or the WHO-E gene primer set. Surprisingly, we initially detected a number of N1 and/or N2 positive samples with high cycle threshold values, though after conducting environmental swabbing of the laboratory and verifying with a second independent primer set (WHO-E) and PCR without reverse transcriptase, we showed that these were false positives due to plasmid contamination from a construct expressing the N gene in the general laboratory environment. Our final results indicate that no sampled wildlife were positive for SARS-CoV-2 RNA, and highlight the importance of physically separate locations for the processing of samples for surveillance and experiments that require the use of plasmid DNA containing the target RNA sequence. These negative findings are surprising, given that most published North America studies have found SARS-CoV-2 within their deer populations. The absence of SARS-CoV-2 RNA in populations sampled here may provide insights in to the various environmental and anthropogenic factors that reduce spillover and spread in North American's wildlife populations.

Surveillance of Vermont wildlife in 2021-2022 reveals no detected SARS-CoV-2 viral RNA.

Previous studies have documented natural infections of SARS-CoV-2 in various domestic and wild animals. More recently, studies have been published noting the susceptibility of members of the Cervidae family, and infections in both wild and captive cervid populations. In this study, we investigated the presence of SARS-CoV-2 in mammalian wildlife within the state of Vermont. 739 nasal or throat samples were collected from wildlife throughout the state during the 2021 and 2022 harvest season. Data was collected from red and gray foxes ( Vulpes vulples and Urocyon cineroargentus , respectively), fishers ( Martes pennati ), river otters ( Lutra canadensis ), coyotes ( Canis lantrans ), bobcats ( Lynx rufus rufus ), black bears ( Ursus americanus ), and white-tailed deer ( Odocoileus virginianus ). Samples were tested for the presence of SARS-CoV-2 via quantitative RT-qPCR using the CDC N1/N2 primer set and/or the WHO-E gene primer set. Our results indicate that no sampled wildlife were positive for SARS-CoV-2. This finding is surprising, given that most published North America studies have found SARS-CoV-2 within their deer populations. The absence of SARS-CoV-2 RNA in populations sampled here may provide insights in to the various environmental and anthropogenic factors that reduce spillover and spread in North American's wildlife populations.

CT angiography in the evaluation of acute pulmonary embolus.

OBJECTIVE: The purpose of this study was to assess the appropriate use of CT angiography (CTA) in the diagnostic evaluation of acute pulmonary embolism (PE). MATERIALS AND METHODS: We reviewed a total of 575 CT angiograms obtained to evaluate for PE at a large level 1 trauma teaching hospital from January 2004 through March 2005. Various clinical settings were used for 267 inpatient (46%), 258 emergency department (45%), and 50 outpatient (9%) studies. We excluded CTA performed for other reasons, repeated CTA, and patient records with incomplete clinical data. On the basis of chart review in which the investigators were blinded to final diagnoses, pretest probability of PE according to the Wells criteria was retrospectively assigned to each patient. D-dimer values, when obtained, also were reviewed. The diagnosis of PE was based on final CTA reports. RESULTS: PE was diagnosed in 9.57% of 575 patients. Positivity rates by location were 32 (12%) of the 267 inpatients, 22 (8.5%) of the 258 emergency department patients, and one (2.0%) of the 50 outpatients. Three (< 1%) of the 575 patients had high probability of PE, even though 351 patients had gone directly to CTA. Of the other 572 patients, 158 (28%) had intermediate and 414 (72%) low probability of PE. In the high, intermediate, and low probability groups, two (67%), 24 (15%), and 29 (7%), respectively, of the patients had PE. A D-dimer assay was performed for 224 (39%) of the 575 patients. Thirty-nine (17%) of the 224 patients had normal results (< 0.5 microg/mL); 107 (48%), intermediate results (0.6-2.0 microg/mL); and 78 (35%), abnormal results (> 2.0 microg/mL). In the emergency department cohort, 151 (59%) of 258 patients underwent a D-dimer assay. Thirty-two (21%) of the 151 patients had normal results; 81 (54%), intermediate results; and 38 (25%), abnormal results. Only one patient with a normal D-dimer level and three patients with intermediate D-dimer levels had PE, the equivalent of 3% of each group. The number of CTA examinations ordered for patients with normal and intermediate D-dimer results was 146 (25% of the 575 total studies). Twenty-two (8%) of the 258 emergency department patients had PE, and clinical suspicion of PE was high for 11 (50%), intermediate for 10 (45%), and low for one (5%) of those patients. CONCLUSION: Our data showed suboptimal use of the Wells criteria and subjective overestimation of the probability of PE before ordering of CTA. Although a definitive acceptable PE positivity rate for CTA has not been established, the 10% yield represents overuse of CTA as a screening rather than a diagnostic examination.

[Adaptation of the measurement of plasma and erythrocyte glutathione peroxidase activity on Hitachi 911]. / Adaptation de la mesure de l'activité glutathion peroxydase plasmatique et érythrocytaire sur Hitachi 911.

The aim was to automate the assay of plasma and erythrocyte glutathione peroxidase (GSH-Px) activity using the Hitachi 911 (Boehringer Mannheim). There is a need for a reliable and rapid technique for the determination of GSH-Px activity to evaluate 'the oxidative stress'. The technique used was that proposed by the Randox laboratories (Randox Laboratories Ltd, Ransel test, reference: RS-505). The Hitachi 911 was programmed by adapting the manual Randox technique. Repeatability, reproducibility and linearity were satisfactory, and usual values for plasma and erythrocyte GSH-Px activity were determined. Automation of the Ransel test for determination of GSH-Px activity was very useful for serial assays. In addition, the technique is practical and has good interlaboratory reproducibility.

Effect of barrel design and the inoculation of Acetobacter pasteurianus in wine vinegar production.

The traditional production of wine vinegar is a lengthy process with little or no microbiological control. The aim of this study was to shorten the acetification process via three different strategies: changes in wood type; barrel shape; and the inoculation of an Acetobacter pasteurianus pure culture. The barrel shape was modified by constructing two prototypes with higher liquid-air interface. We compared the changes in acetic acid bacteria (AAB) population dynamics in these barrels with those of a submerged method. The wood type had no effect on the acetification length, whereas the shape of the barrel resulted in a significant shortening of the acetification length. Although the selected AAB strain did not always take over, it reduced the biodiversity of the AAB. The inoculated strain was predominant in oak barrels, whereas in the highly aerated prototypes Gluconacetobacter species (Ga. intermedius and/or Ga. europaeus) displaced A. pasteurianus, as what occurs in the submerged method.

Arritmias y embarazo / Arrhythmias in pregnancy

Las modificaciones hemodinámicas y hormonales ligadas al embarazo, así como la presencia de una cardiopatía estructural subyacente son factores que pueden precipitar la aparición de arritmias. Generalmente son de fácil manejo y su presencia en gestantes no suele comportar consecuencias graves para el feto o para la madre. En otras ocasiones, sin embargo pueden acarrear un riesgo vital para ambos. Reconocer el tipo de arritmia y su repercusión hemodinámica es importante para plantear la estrategia terapéutica. Es fundamental conocer el perfil de seguridad de los antiarrítmicos disponibles y utilizarlos a las dosis adecuadas. El soporte vital avanzado implica una serie de peculiaridades que conviene recordar a la hora de someter a la embarazada a maniobras de resucitación. El objetivo de esta revisión es poner al día el conocimiento de esta patología con el fin de proporcionar los cuidados adecuados para la madre y el feto (AU)

The hemodynamic and hormonal changes of pregnancy and the presence of underlying structural heart disease are factors that can lead to arrhythmias. In general, such arrhythmias can be easily managed and have no serious consequences for mother or fetus. Occasionally, however, they can be life-threatening for both. It is important to be able to identify the type of arrhythmia present and understand its hemodynamic effects in order to plan a management approach. Knowledge of the safety profile of available antiarrhythmia agents and their appropriate dosages will also be required. A series of special circumstances must be taken into consideration when undertaking resuscitation maneuvers for advanced life support in pregnancy. Our aim is to review current knowledge that is necessary for providing adequate care for mother and fetus when arrhythmias develop (AU)